U.S. Markets open in 1 hr 21 mins

Blog Coverage: Concord Medical Announced Acquisition of Shanghai ProMed Cancer Center under Its High-End Cancer Hospital Development Strategy

Upcoming AWS Coverage on Community Health Systems Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Concord Medical Services Holdings Ltd. (NYSE: CCM) as the Company announced on May 19, 2017, that its subsidiary, Meizhong Jiahe Hospital Management Corp. Ltd, previously known as CMS Hospital Management Co., Ltd, jointly with Guofu Huimei Investment Management Limited Partnership, has proposed to acquire Shanghai ProMed Cancer Center, LLC by purchasing existing, and subscribing for newly released, registered capital of ProMed. Post the acquisition, MHM will hold 31.64% of the equity interest in ProMed Cancer Center. Register with us now for your free membership and blog access at:


One of Concord Medical Services Holdings' competitors within the Hospitals space, Community Health Systems, Inc. (NYSE: CYH), announced on May 01, 2017, its financial and operating results for the three months ended March 31, 2017. AWS will be initiating a research report on Community Health Systems in the coming days.

Today, AWS is promoting its blog coverage on CCM; touching on CYH. Get all of our free blog coverage and more by clicking on the link below:


Breaking down the Announcement

This announcement is viewed as a critical point for the Company's long-term strategy of developing a specialized cancer hospital in China. Post the acquisition, ProMed will be the flagship cancer center under Meizhong Jiahe brand and will deliver an additional regional advantage, an independent medical institution license and high-end equipment. Additionally, the Company will upgrade the service procedure and clinical skills to offer best-in-class treatment. Concord Medical will enable quality management and talent training system by cooperating with prominent cancer treatment institutions across the world, by providing better cancer diagnosis and treatment.

ProMed's Portfolio

ProMed has a comprehensive portfolio of advanced medical equipment, such as linear accelerators, Cts, MRIs, Mo-target mammography, CDFI, and telepathology consultation systems. Located on the campus of Shanghai Ruijin Hospital, Luwan Brand, the cancer center offers a multitude of medical resources for the patients. Promed's outpatient cancer clinic offers medical services including diagnostic imaging, radiation oncology, medical oncology such as chemotherapy, targeted therapy, and immunization therapy to its patients. Additionally, ProMed is collaborating with multiple international cancer treatment institutions to enable better patient cure rate and life expectancy. ProMed will deliver high-end clinical tumor diagnosis and treatment services to public medical insured patients and business insured patients as well.

Concord Growth Prospects

Concord Medical is a leading specialty hospital management solution provider and operator of China's largest network of radiotherapy and diagnostic imaging centers. The Company currently operates through a network of 123 centers with 73 hospital partners across 52 cities and 25 provinces and administrative regions in China. Concord delivers radiotherapy and diagnostic imaging equipment in long-term collaboration with top-tier hospital in China and manages the operational end of these test centers. The Company acquired Concord Cancer Hospital, a private hospital in Singapore, April 2015 under an attempt to expand its high-end cancer hospital development strategy and oversea business extension.

Concord Medical recently signed an agreement with Ion Beam Applications S.A., for the purchase, installation, and maintenance of proton theory which is scheduled to be installed at Beijing Proton Medical Center. The Beijing Medical Center is jointly developed by Concord Medical and China-Japan Friendship Hospital. IBA's proton theory has been used to treat more cancer patients that any other Company in the world. This extensive experience and knowledge of proton theory treatment have enabled IBA to ensure that more patients are able to get this highly accurate form of cancer treatment.

In January 2016, the Company acquired 100% equity interest in Beijing Century Friendship and an additional 55% equity interest in Beijing Proton Medical Center with a total consideration of RMB 100.6 million and ultimately held 80% equity interest in Beijing Proton Medical Center.

Stock Performance

At the close of trading session on Friday, May 19, 2017, Concord Medical Services' stock price was marginally down by 0.72% to end the day at $4.16. A total volume of 10.58 thousand shares were exchanged during the session. The Company's share price has surged 15.88% in the past twelve months. Concord Medical's stock has a net market capital of $181.21 million as per Friday's last closing price.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street